Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation

Vittorio Montefusco, Francesco Spina, Francesca Patriarca, Massimo Offidani, Benedetto Bruno, Mauro Montanari, Alberto Mussetti, Alessandra Sperotto, Ilaria Scortechini, Anna Dodero, Renato Fanin, Pinuccia Valagussa, Paolo Corradini

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess the safety and efficacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range, 33 to 67); 14 patients were allografted from human leukocyte antigen-identical siblings and 5 from alternative donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients because of disease progression and 1 refused. After the VD phase the response rate was 62%, with 1 complete remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with progressive disease. After the DLI phase, the response rate was 68%, but a significant upgrade of response was observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months (range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31% and 73%, respectively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-host disease flares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective.

Original languageEnglish
Pages (from-to)424-428
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Dexamethasone
Tissue Donors
Lymphocytes
Bortezomib
Graft vs Host Disease
HLA Antigens
Disease-Free Survival
Disease Progression
Siblings
Therapeutics
Survival Rate
Safety

Keywords

  • Allogeneic stem cell transplantation
  • Bortezomib
  • Donor lymphocyte infusions
  • Multiple myeloma

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. / Montefusco, Vittorio; Spina, Francesco; Patriarca, Francesca; Offidani, Massimo; Bruno, Benedetto; Montanari, Mauro; Mussetti, Alberto; Sperotto, Alessandra; Scortechini, Ilaria; Dodero, Anna; Fanin, Renato; Valagussa, Pinuccia; Corradini, Paolo.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 3, 03.2013, p. 424-428.

Research output: Contribution to journalArticle

Montefusco, Vittorio ; Spina, Francesco ; Patriarca, Francesca ; Offidani, Massimo ; Bruno, Benedetto ; Montanari, Mauro ; Mussetti, Alberto ; Sperotto, Alessandra ; Scortechini, Ilaria ; Dodero, Anna ; Fanin, Renato ; Valagussa, Pinuccia ; Corradini, Paolo. / Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 3. pp. 424-428.
@article{65790ea00e5043859725691c42bb795e,
title = "Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation",
abstract = "Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess the safety and efficacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range, 33 to 67); 14 patients were allografted from human leukocyte antigen-identical siblings and 5 from alternative donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients because of disease progression and 1 refused. After the VD phase the response rate was 62{\%}, with 1 complete remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with progressive disease. After the DLI phase, the response rate was 68{\%}, but a significant upgrade of response was observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months (range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31{\%} and 73{\%}, respectively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-host disease flares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective.",
keywords = "Allogeneic stem cell transplantation, Bortezomib, Donor lymphocyte infusions, Multiple myeloma",
author = "Vittorio Montefusco and Francesco Spina and Francesca Patriarca and Massimo Offidani and Benedetto Bruno and Mauro Montanari and Alberto Mussetti and Alessandra Sperotto and Ilaria Scortechini and Anna Dodero and Renato Fanin and Pinuccia Valagussa and Paolo Corradini",
year = "2013",
month = "3",
doi = "10.1016/j.bbmt.2012.10.032",
language = "English",
volume = "19",
pages = "424--428",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation

AU - Montefusco, Vittorio

AU - Spina, Francesco

AU - Patriarca, Francesca

AU - Offidani, Massimo

AU - Bruno, Benedetto

AU - Montanari, Mauro

AU - Mussetti, Alberto

AU - Sperotto, Alessandra

AU - Scortechini, Ilaria

AU - Dodero, Anna

AU - Fanin, Renato

AU - Valagussa, Pinuccia

AU - Corradini, Paolo

PY - 2013/3

Y1 - 2013/3

N2 - Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess the safety and efficacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range, 33 to 67); 14 patients were allografted from human leukocyte antigen-identical siblings and 5 from alternative donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients because of disease progression and 1 refused. After the VD phase the response rate was 62%, with 1 complete remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with progressive disease. After the DLI phase, the response rate was 68%, but a significant upgrade of response was observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months (range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31% and 73%, respectively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-host disease flares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective.

AB - Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess the safety and efficacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range, 33 to 67); 14 patients were allografted from human leukocyte antigen-identical siblings and 5 from alternative donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients because of disease progression and 1 refused. After the VD phase the response rate was 62%, with 1 complete remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with progressive disease. After the DLI phase, the response rate was 68%, but a significant upgrade of response was observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months (range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31% and 73%, respectively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-host disease flares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective.

KW - Allogeneic stem cell transplantation

KW - Bortezomib

KW - Donor lymphocyte infusions

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84873730625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873730625&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.10.032

DO - 10.1016/j.bbmt.2012.10.032

M3 - Article

VL - 19

SP - 424

EP - 428

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -